Archives of neurology
-
Archives of neurology · Aug 2008
Randomized Controlled Trial Multicenter Study Comparative StudyPhase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease. ⋯ LY450139 was generally well tolerated at doses of up to 140 mg/d for 14 weeks, with several findings indicating the need for close clinical monitoring in future studies. Decreases in plasma Abeta concentrations were consistent with inhibition of gamma-secretase. Trial Registration clinicaltrials.gov Identifier: NCT00244322.